




## siRNA expression vector pRNATin-H1.2/Neo/siFLuc (Catalogue No.: SD1523)

**Description:** pRNATin-H1.2/Neo/siFLuc is a GenScript siRNA expression vector. It is designed for mammalian transfection. The GFP marker (coral GFP, cGFP) under CMV promoter control can be used to track the transfection efficiency. It uses the H1.2 promoter, an engineered inducible promoter containing a tetracycline operator (TetO1) for siRNA expression. This vector contains siRNA construct for Firefly luciferase, and can be used as a positive control. It can also be used as a siRNA vector using BamH I and Hind III for siRNA insertion.



**Polylinker:** 6168-64  
**H1 Promoter:** 6068-6167  
**CMV Promoter:** 103-691  
**cGFP:** 707-1426  
**SV40 Promoter:** 2115-2460  
**Neomycin:** 2501-3295  
**pUC ori:** 4009-4649  
**Ampicillin:** 4797-5657

**Forward Sequencing Primer:**  
[DA0013: pRNA-H1 Forward](#)  
 (TAATACGACTCACTATAGGG)  
**Reverse Sequencing Primer:**  
[DA0012: pRNA Reverse](#)  
 (TAGAAGGCACAGTCGAGG)



\* **Limited Use Label License:** This product is covered by United States Patent Applications No. 60/505,677, owned by GenScript Corporation. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the siRNA synthesis methods claimed in the patent application for research and development purposes solely in conjunction with this product.

\*\* **Limited Use Label License:** The use of CMV promoter is covered under U. S. Patent No. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and is sold for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation (UIRF), 214 Technology Innovation Center, Iowa City, Iowa 52242. For further information, please contact the Associate Director of UIRF, at 319-335-4546.